CBD for PMS and period pain: what the studies say

Period pain, or dysmenorrhoea, is lower-abdominal pain that comes just before or during a period. According to the Assurance maladie, France's national health insurance, 50 to 70% of adolescent girls have painful periods, every time or occasionally. It describes two forms. Primary dysmenorrhoea starts a few months after the first period. It is linked to an excess of prostaglandins made by the lining of the uterus, and it is usually benign. Secondary dysmenorrhoea starts later, after periods that used to be painless, and a cause is always sought: endometriosis, adenomyosis, a fibroid, a polyp or a badly placed IUD.

PMS is a separate condition: a set of symptoms that start a few days before a period. The Assurance maladie lists swollen, tender breasts, a bloated abdomen, swollen hands and feet, irritability or anxiety, and headaches. The American College of Obstetricians and Gynecologists (ACOG) gives a definition anchored in the dates of the cycle. The symptoms must be present in the 5 days before a period for at least three cycles in a row, and end within 4 days of its start.

The severe form is called premenstrual dysphoric disorder, and mood symptoms dominate it. A 2024 meta-analysis in the Journal of Affective Disorders, pooling 44 studies and 50,659 participants, puts its frequency at 3.2% when the diagnosis is confirmed by daily tracking over two cycles. On a provisional diagnosis, the figure is 7.7%.

No controlled trial of CBD in PMS or primary dysmenorrhoea has been published. The closest registered trial, NCT04091789, was filed in the United States in 2019 by a company. It describes a tablet combining 30 mg of CBD, 1 mg of THC and palmitoylethanolamide, given to a single group with no placebo and 30 planned participants. Its status reads "unknown", and no results have been published.

Human data come from surveys. The latest, published in 2026 in the Journal of Women's Health, polled 703 people in the United States online. Of these, 634 had menstruated in the past year and 167 had premenstrual dysphoric disorder. To manage premenstrual mood, 30.0% used cannabis and 16.1% used alcohol. Among those with the dysphoric disorder, 51.5% used cannabis, mostly in the two weeks before a period. The study has three limits: its sample was self-selected, it measures use without measuring effect, and it covers cannabis in general, THC included.

A 2024 survey in Germany, Austria and Switzerland reached 912 people with endometriosis through patient groups on social media; 114 of them used cannabis. What such self-reports are worth is discussed in our article on CBD and endometriosis. A 2022 narrative review calls cannabis a "promising" avenue, yet the trials it lists deal with pain in general and none with periods.

In the other direction, the food safety commission of the German Research Foundation (SKLM) reviewed the evidence in 2025. It found no scientific evidence supporting a health claim for CBD at the doses present in food products, menstrual health included. Our summary of what clinical studies say about CBD gives the wider picture.

MILDECA, the French interministerial mission for combating drugs, states the rule plainly: unless authorised as a medicine, products containing CBD may not make therapeutic claims, on pain of criminal penalties. Epidyolex, prescribed in certain rare epilepsies, is the only authorised cannabidiol-based medicine, and our article on Epidyolex explains its framework. A shop that promises an oil will "calm period pain" is breaking the law, which is a good reason to buy elsewhere.

The sale itself depends on a threshold of 0.30% Δ⁹-THC in the finished product. The Conseil d'État decision of 29 December 2022 overturned the ban on selling raw flowers and leaves. CBD you swallow also comes under the novel food regime, which our overview of CBD regulation in 2026 describes.

Start with the dose. On 9 February 2026, EFSA set a provisional limit of 0.0275 mg of CBD per kilo of body weight per day, about 2 mg a day for a 70 kg adult. The limit applies to food supplements made with CBD of at least 98% purity. According to the agency, safety cannot be established under the age of 25, during pregnancy or breastfeeding, or for people on medication. Our article on EFSA's reference dose works through the calculation.

Medicines come next. According to the European product information for Epidyolex, CBD is broken down by the liver enzymes CYP3A4 and CYP2C19, and it raises exposure to the active metabolite of clobazam 3 to 4 times. The document says nothing about hormonal contraceptives. The absence of a documented interaction there does not prove that none exists. If you take any treatment, anti-inflammatories included, ask your pharmacist. Our article on the grapefruit effect explains the mechanism.

Last, pregnancy. CBD is advised against when you are trying to conceive, pregnant or breastfeeding, and our article on CBD during pregnancy gives the reasons.

For painful periods, the Assurance maladie's first advice is heat, from a hot water bottle or a warm bath, and gentle exercise such as walking or swimming. It names anti-inflammatories as the most effective medicines, taken early, at the lowest effective dose and for no more than 2 to 3 days.

The same source lists the situations that call for a consultation:

• pain that anti-inflammatories do not ease, or that lasts more than a few days;
• pain that starts for the first time in adulthood, or worsens from one cycle to the next;
• pain that keeps you from your usual activities;
• fever, unusual discharge, bleeding between periods, or very heavy periods;
• pain during intercourse.

Each of these signs may point to a cause that needs treatment, endometriosis for instance. Do not let any wellbeing habit, CBD included, push back that appointment.